Arix Bioscience plc’s portfolio company Aura completes $40 million Series D financing

  • Arix’s total interest in Aura increases to £8.5 million from £3.9 million
  • Arix commits $4.5million (£3.4 million[1]) to increase its stake to 7.7%
  • Proceeds to be used to support late stage clinical development; Phase 3 trial expected to start in H1 2020

LONDON, 2 April 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing and building breakthrough biotech companies, today announces that it has committed $4.5 million (£3.4 million1) to the $40 million (£31 million) Series D financing (“the financing”) of Aura Biosciences (“Aura”), a leader in the development of novel targeted therapies in ocular oncology.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH